Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saye Khoo

Showing results (31-40 of 282) with videos related to

Pageof 29
Sort By:
AIDS (London, England)|January 10, 2015
A case of iatrogenic adrenal suppression after co-administration of cobicistat and fluticasone nasal dropsJoe Lewis, Lance Turtle, Saye Khoo, et al.
AIDS (London, England)|August 11, 2007
Stopping antiretroviral therapyStephen Taylor, Marta Boffito, Saye Khoo, et al.
Therapeutic Drug Monitoring|May 29, 2007
Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individualsLaura Dickinson, David Back, Anton Pozniak, et al.
Clinical Pharmacokinetics|December 14, 2021
Drug-Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis InfectionCatia Marzolini, Sara Gibbons, Joep J van Oosterhout, et al.
The Journal of Infectious Diseases|February 25, 2003
Differential expression of human immunodeficiency virus coreceptors, by CEM, CEMVBL, and CEM E1000 cellsAndrew Owen, Becky Chandler, Jenny Ford, et al.
Journal of the International AIDS Society|November 14, 2014
Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?Andrew Hill, Saye Khoo, David Back, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 9, 2014
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countriesAndrew Hill, Saye Khoo, Joe Fortunak, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 18, 2005
Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometryLaura Dickinson, Lesley Robinson, John Tjia, et al.
Antimicrobial Agents and Chemotherapy|May 26, 2019
Reply to Banda et al., "Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine"Stephen Walimbwa, Mohammed Lamorde, Catriona Waitt, et al.
Journal of Clinical Pharmacy and Therapeutics|November 3, 2022
The effect of changing to Bictegravir on lipids using real world data: A brief reportThomas Heseltine, Elen Hughes, Jean Mathew, et al.
Pageof 29

Showing results (31-40 of 282) with videos related to

Sort By:
Pageof 29
AIDS (London, England)|January 10, 2015
A case of iatrogenic adrenal suppression after co-administration of cobicistat and fluticasone nasal dropsJoe Lewis, Lance Turtle, Saye Khoo, et al.
AIDS (London, England)|August 11, 2007
Stopping antiretroviral therapyStephen Taylor, Marta Boffito, Saye Khoo, et al.
Therapeutic Drug Monitoring|May 29, 2007
Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individualsLaura Dickinson, David Back, Anton Pozniak, et al.
Clinical Pharmacokinetics|December 14, 2021
Drug-Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis InfectionCatia Marzolini, Sara Gibbons, Joep J van Oosterhout, et al.
The Journal of Infectious Diseases|February 25, 2003
Differential expression of human immunodeficiency virus coreceptors, by CEM, CEMVBL, and CEM E1000 cellsAndrew Owen, Becky Chandler, Jenny Ford, et al.
Journal of the International AIDS Society|November 14, 2014
Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?Andrew Hill, Saye Khoo, David Back, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 9, 2014
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countriesAndrew Hill, Saye Khoo, Joe Fortunak, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 18, 2005
Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometryLaura Dickinson, Lesley Robinson, John Tjia, et al.
Antimicrobial Agents and Chemotherapy|May 26, 2019
Reply to Banda et al., "Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine"Stephen Walimbwa, Mohammed Lamorde, Catriona Waitt, et al.
Journal of Clinical Pharmacy and Therapeutics|November 3, 2022
The effect of changing to Bictegravir on lipids using real world data: A brief reportThomas Heseltine, Elen Hughes, Jean Mathew, et al.
Pageof 29